Channel 4 is set to bring Gilead’s gripping story to a close with the sixth and final season of the award-winning series, The ...

It’s time for a revolution on The Handmaid’s Tale. The trailer for the sixth and final season has dropped ahead of its ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Cambridge has been used as Gilead on numerous occasions. In the very first season, there’s a moment where the Handmaids walk over a bridge with white arches. That’s across the Grand River.

Gilead’s (NASDAQ:GILD ... The data was presented at the 66th American Society of Hematology Annual Meeting, which is being held Dec. 7-10 in San Diego. Yescarta is approved to treat certain ...

They are affecting lives and shaping outcomes in our society right now in the 21st Century.” “From the Margins” will also be used by Gilead Sciences as a catalyst to try and affect changes ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...